Using the TCGA, we found that head and neck cancer patients have higher MK2 gene expression compared to non-cancer patients and MK2 transcript levels increased with worsening tumor grade (Fig. 1A and B). The gene discussed is MAPKAPK2; the disease is head and neck cancer.